<DOC>
	<DOC>NCT00848536</DOC>
	<brief_summary>A Multi-Center Double-masked Study of the Safety and Efficacy of Travoprost APS Compared to TRAVATAN in Patients with Open-angle Glaucoma or Ocular Hypertension</brief_summary>
	<brief_title>Efficacy Study of Travoprost APS Versus TRAVATAN</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>18 years of age or older, either gender and any race. Open Angle Glaucoma (OAG) or Ocular Hypertension (OHT). Not currently on any IOPlowering medication or currently on a stable treatment (i.e, at least 30 days) with and IOPlowering monotherapy. All patients: Mean IOP in same eye (at both Eligibility 1 &amp; 2 Visits): ≥ 24 and ≤ 36 mmHg at 9 AM; and ≥ 21 and ≤ 36 mmHg at 11 AM &amp; 4 PM. Other protocoldefined inclusion criteria may apply. Females of childbearing potential not meeting conditions set in the protocol. Severe central visual field loss. Angle Shaffer grade &lt; 2. Cup/disc ratio &gt; 0.8 (horizontal or vertical measurement). Best corrected visual acuity (VA) score worse than 55 ETDRS letters read (equivalent to approximately 20/80 Snellen or 0.25 decimal). Intraocular surgery or trauma within last 6 months. Any abnormality preventing reliable applanation tonometry. History of or current ocular pathology (including severe dry eye) that would affect the conduct of the study. Allergy/hypersensitivity to study medications. Unable to discontinue use of all IOPlowering medications for a minimum washout period of 5 to 28 days prior to the Eligibility Visit. Less than 30 days stable dosing regimen of medications used on a chronic basis that may affect IOP. Use of any additional topical or systemic ocular hypotensive medication during the study. Therapy with another investigational agent within 30 days prior to the Screening visit. Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>OAG</keyword>
	<keyword>OHT</keyword>
</DOC>